

ASX Announcement

8 September 2026

100th Patient Treated with OncoSil™ device in Spain

Key highlights

- The 100th patient has been treated with the OncoSil™ device in Spain, representing a significant milestone in the Company's continued commercial expansion in the country.
- The milestone procedure was performed at Hospital HM Sanchinarro, Madrid on 7 September 2026, demonstrating continued clinical adoption of the OncoSil™ treatment across Spain.
- Spain represents an important European market for OncoSil Medical, with approximately 9,200 new pancreatic cancer cases diagnosed annually, highlighting the significant patient population and unmet clinical need.
- OncoSil Medical now has 11 active treatment sites across Spain, providing an established platform to drive increased utilisation and broaden patient access to the OncoSil™ treatment.

Sydney, Australia – 8 September 2026: OncoSil Medical Limited (ASX: OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce that the 100th patient in Spain has been treated with the OncoSil™ device. The milestone treatment took place at Hospital HM Sanchinarro, Madrid on 7 September 2026, marking an important achievement in the continued adoption and clinical use of the OncoSil™ device in Spain.

Spain is an important European market for OncoSil Medical, with approximately 9,200 new cases of pancreatic cancer diagnosed in the country each year¹. This significant disease burden, together with the growing engagement of leading pancreatic cancer treatment centres, underpins the strategic importance of Spain to the Company's European commercialisation strategy.

OncoSil Medical currently has 11 active treatment sites across Spain, providing an expanding network of hospitals and clinicians with access to the OncoSil™ treatment for eligible patients with unresectable locally advanced pancreatic cancer. Reaching the 100-patient milestone reflects the continued engagement of Spanish clinicians and treatment centres and represents further progress in the adoption and utilisation of the OncoSil™ device into clinical practice.

The Company remains focused on strengthening its presence in Spain by supporting existing treatment centres, increasing utilisation across active sites and expanding the network of hospitals offering the OncoSil™ treatment.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

“Reaching our 100th patient treatment in Spain is an important milestone for OncoSil Medical and demonstrates the continued progress we are making in one of our key European markets. We are particularly encouraged by the growing engagement from clinicians and hospitals across Spain.

With 11 active treatment sites in the country, our focus is increasingly on driving utilisation across this network and ensuring that more eligible pancreatic cancer patients can access the OncoSil™ treatment.

We would like to thank the clinical teams across Spain whose commitment and expertise have enabled us to reach this milestone, and particularly the team at Hospital HM Sanchinarro responsible for treating our 100th patient.”

Click [here](#) to view this announcement on Investor Hub.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 9642 4981	Mr. Tim Luscombe & Ms. Nova Taylor Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703
--	--

About OncoSil Medical

OncoSil Medical (ASX) is a global medical device company focused on Interventional Oncology, with a mission to improve outcomes for people living with cancer. The company has developed OncoSil™, a single-use brachytherapy (internal radiation) device that delivers a pre-determined dose of beta radiation directly into cancerous tissue using targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles. Its targeted approach enables a greater radiation dose to be delivered directly to the tumour while limiting exposure to surrounding critical organs.

In the United States, OncoSil™ is indicated for the treatment of patients with distal cholangiocarcinoma (dCCA) that is both unresectable (locally advanced and/or unfit for surgery) and non-metastatic, as an adjunct to systemic therapy. In markets outside the United States where OncoSil™ has received regulatory approval, OncoSil™ is indicated for the treatment of patients with unresectable locally advanced pancreatic cancer, in addition to gemcitabine-based chemotherapy.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival. Distal cholangiocarcinoma (dCCA) is a rare form of bile duct cancer. It is often diagnosed at an advanced stage, when surgical treatment may no longer be possible, and is associated with a poor prognosis.

OncoSil™ has received CE Marking approval, providing marketing authorisation in the European Union and the United Kingdom. OncoSil™ has also received approval from the U.S. Food and Drug Administration (FDA) under a Humanitarian Device Exemption (HDE) for the treatment of patients with unresectable, non-metastatic distal cholangiocarcinoma (dCCA), as an adjunct to systemic therapy. OncoSil™ has been designated as a Breakthrough Device in Europe and the United States. It is currently approved for sale in 30+ countries, including the European Union, United Kingdom, United States, Australia, Saudi Arabia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>